Regen Innopharm Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$3.73M
- Investors
-
4
Regen Innopharm General Information
Description
Operator of a regenerative medicine company intended to repair damaged tissues by activating endogenous stem cells. The company utilizes a molecular platform and a wake-up stem cell system to develop RNA-based drugs, peptide-based drugs, diabetic foot ulcer therapeutics, acute myocardial infarction therapeutics, and ischemic stroke therapeutics, enabling healthcare providers to use cell-free treatments to regenerate tissues and improve patient outcomes.
Contact Information
Website
www.regeninnopharm.comCorporate Office
- Room 5008, Catholic Institute of Biomedical Industry
- 222 Banpo-daero, Seocho-gu
- Seoul, 06591
- South Korea
Corporate Office
- Room 5008, Catholic Institute of Biomedical Industry
- 222 Banpo-daero, Seocho-gu
- Seoul, 06591
- South Korea
Regen Innopharm Timeline
Regen Innopharm Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series A) | 09-Nov-2026 | $3.73M | Completed | Pre-Clinical Trials | ||
| 4. Early Stage VC (Series A) | 06-Dec-2023 | Cancelled | Pre-Clinical Trials | |||
| 3. Seed Round | 01-Mar-2025 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 01-Jan-2025 | $548K | Completed | Pre-Clinical Trials | ||
| 1. Seed Round | 01-Jan-2021 | $548K | $548K | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Regen Innopharm Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Regen Innopharm Patents
Regen Innopharm Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4321527-A1 | Cell-penetrating peptide variant and use thereof | Pending | 07-Apr-2021 | ||
| EP-4321527-A4 | Cell-penetrating peptide variant and use thereof | Pending | 07-Apr-2021 | ||
| US-20240182521-A1 | Cell-penetrating peptide variant and use thereof | Pending | 07-Apr-2021 | ||
| WO-2022215946-A1 | Cell-penetrating peptide variant and use thereof | Inactive | 07-Apr-2021 | ||
| EP-4279091-A1 | Composition comprising mir 145 inhibitor as active ingredient for treatment of myocardial infarction | Pending | 18-Jan-2021 | C12N15/113 |
Regen Innopharm Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Regen Innopharm Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Partners Investment | Venture Capital | Minority | ||
| Aimedbio | Corporation | Minority | ||
| DAYLI Partners | Venture Capital | Minority | ||
| Tech Incubator Program for Startup | Accelerator/Incubator |
Regen Innopharm FAQs
-
When was Regen Innopharm founded?
Regen Innopharm was founded in 2019.
-
Where is Regen Innopharm headquartered?
Regen Innopharm is headquartered in Seoul, South Korea.
-
What is the size of Regen Innopharm?
Regen Innopharm has 6 total employees.
-
What industry is Regen Innopharm in?
Regen Innopharm’s primary industry is Biotechnology.
-
Is Regen Innopharm a private or public company?
Regen Innopharm is a Private company.
-
What is Regen Innopharm’s current revenue?
The current revenue for Regen Innopharm is .
-
How much funding has Regen Innopharm raised over time?
Regen Innopharm has raised $5.67M.
-
Who are Regen Innopharm’s investors?
Partners Investment, Aimedbio, DAYLI Partners, and Tech Incubator Program for Startup have invested in Regen Innopharm.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
